Hip Arthroscopy
1
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Geistlich PharmaSwitzerland - Root
1 program1
Autologous matrix-induced chondrogenesisPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
2027
2028
2029
2030
2031
Geistlich PharmaAutologous matrix-induced chondrogenesis
ArthrexHip Arthroscopy
Clinical Trials (2)
Total enrollment: 40 patients across 2 trials
AMIC Compared With Microfracture for Focal Articular Cartilage Damage of the Hip
Start: Mar 2023Est. completion: Jan 202740 patients
Phase 1Recruiting
An Evaluation of Hip Preservation Outcomes
Start: Jun 2023Est. completion: Jun 2053
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 40 patients
2 companies competing in this space